Imperva (IMPV) Lowered to Hold at Zacks Investment Research

Imperva (NASDAQ:IMPV) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.

According to Zacks, “Imperva Inc. is engaged in the development of protection software and services for business applications and databases. The Company delivers innovative technology to give full audit accountability and separation of duties to meet regulatory compliance. It offers SecureSphere Data Security Suite to protect sensitive data from hackers and malicious insiders along with providing a fast and cost-effective route to regulatory compliance and establishes a repeatable process for data risk management. The Company’s SecureSphere offers database security solutions to secure sensitive data stored in databases, File Security solutions to protect sensitive files on file servers, storage devices, content repositories, and meet regulatory compliance mandates and Web Application Security solutions to protect web applications from cyber attacks. Imperva Inc. is headquartered in Redwood Shores, California. “

Several other equities research analysts have also recently weighed in on the company. BidaskClub upgraded Imperva from a “sell” rating to a “hold” rating in a report on Friday, January 5th. JPMorgan Chase & Co. cut Imperva from a “neutral” rating to an “underweight” rating and set a $45.00 target price for the company. in a report on Tuesday, December 12th. Morgan Stanley restated an “underweight” rating and set a $39.00 target price on shares of Imperva in a report on Thursday, November 9th. Oppenheimer restated a “buy” rating and set a $55.00 target price on shares of Imperva in a report on Thursday, November 9th. Finally, Stifel Nicolaus restated a “hold” rating and set a $47.00 target price (down from $50.00) on shares of Imperva in a report on Thursday, November 9th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $51.86.

Imperva (NASDAQ IMPV) opened at $43.80 on Wednesday. Imperva has a fifty-two week low of $37.17 and a fifty-two week high of $52.40. The stock has a market capitalization of $1,490.00, a PE ratio of 162.22 and a beta of 1.78.

Imperva (NASDAQ:IMPV) last issued its earnings results on Wednesday, November 8th. The software maker reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.11. The company had revenue of $83.89 million during the quarter, compared to analysts’ expectations of $83.79 million. Imperva had a negative return on equity of 8.52% and a net margin of 3.04%. Imperva’s quarterly revenue was up 22.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.08 EPS. analysts expect that Imperva will post -0.52 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Van ECK Associates Corp raised its position in Imperva by 0.8% during the 2nd quarter. Van ECK Associates Corp now owns 8,346 shares of the software maker’s stock valued at $399,000 after purchasing an additional 64 shares during the last quarter. Comerica Bank raised its position in Imperva by 0.8% during the 2nd quarter. Comerica Bank now owns 19,707 shares of the software maker’s stock valued at $978,000 after purchasing an additional 157 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in Imperva by 18.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,940 shares of the software maker’s stock valued at $141,000 after purchasing an additional 464 shares during the last quarter. Parametric Portfolio Associates LLC raised its position in Imperva by 5.3% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 11,614 shares of the software maker’s stock valued at $556,000 after purchasing an additional 581 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. raised its position in Imperva by 26.2% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,177 shares of the software maker’s stock valued at $201,000 after purchasing an additional 866 shares during the last quarter. 96.93% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Imperva (IMPV) Lowered to Hold at Zacks Investment Research” was reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.themarketsdaily.com/2018/01/10/imperva-impv-lowered-to-hold-at-zacks-investment-research.html.

Imperva Company Profile

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.

Get a free copy of the Zacks research report on Imperva (IMPV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Imperva (NASDAQ:IMPV)

Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply